Although there are discrepancies about whether or not IFN-γ therapy increases serum NO levels in CGD patients [77], many authors have found that prolonged IFN-γ treatment enhances the generation of NO through the activity of TNF-α [135]. The gene discussed is TNF; the disease is chronic granulomatous disease.